ethyl N- allyl- N- (2- methyl- 3- (4- (4- amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate

structure given in first source

Also Known As:

ONO 3403; ONO-3403

Networked: 10 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Acyclic Hydrocarbons
    - Alkenes: 265
      - Allyl Compounds: 7
        Allylglycine: 43
        ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate: 10
- Amidines: 14
  - Benzamidines: 5
    - ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate: 10
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Glycine: 5151
    - Allylglycine: 43
      - ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate: 10

Experts

1.	Ohkoshi, Motohiro: 3 articles (09/2009 - 03/2002)
2.	Hiwasa, Takaki: 2 articles (02/2011 - 04/2002)
3.	Fujikawa, Haruka: 1 article (12/2016)
4.	Ishigami, Akihito: 1 article (12/2016)
5.	Kai, Hirofumi: 1 article (12/2016)
6.	Kamei, Shunsuke: 1 article (12/2016)
7.	Kawakami, Taisei: 1 article (12/2016)
8.	Kitamura, Kenichiro: 1 article (12/2016)
9.	Kondo, Yoshitaka: 1 article (12/2016)
10.	Li, Jian-Dong: 1 article (12/2016)

Related Diseases

1.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/01/2001 - "The results suggest that ONO-3403 may be useful for the treatment of squamous cell carcinoma." 05/01/1997 - "The half maximum inhibition concentrations of ONO-3403 toward BxPC-3 pancreatic carcinoma, T24 bladder carcinoma and A431 epidermoid carcinoma cells were 20-30 mu g/ml whereas those toward pancreatic carcinomas, PANC-1 and Mia PaCa-2, were 60-80 mu g/ml. Since FOY-305 has been shown to be effective in chemotherapy for human oral cancer, ONO-3403 is expected to be a more effective anticancer drug."
2.	Carcinoma (Carcinomatosis) 03/01/2002 - "In the present study, oral administration of ONO-3403 was used to challenge 3-methylcholanthrene-induced carcinoma. " 04/01/2002 - "Treatment of T.Tn human esophageal carcinoma cells with ONO-3403 caused also decrease in pY-p180, which appeared to be epidermal growth factor receptor. " 05/01/1997 - "Growth-suppressive activities of serine protease inhibitors, FOY-305, ONO-3403 and FO-349 toward human carcinoma cells." 05/01/1997 - "The half maximum inhibition concentrations of ONO-3403 toward BxPC-3 pancreatic carcinoma, T24 bladder carcinoma and A431 epidermoid carcinoma cells were 20-30 mu g/ml whereas those toward pancreatic carcinomas, PANC-1 and Mia PaCa-2, were 60-80 mu g/ml. Since FOY-305 has been shown to be effective in chemotherapy for human oral cancer, ONO-3403 is expected to be a more effective anticancer drug."
3.	Pulmonary Emphysema 12/16/2016 - "Treatments of C57/BL6J-βENaC-Tg mice with a serine protease inhibitor ONO-3403, a derivative of camostat methylate (CM), but not CM, and with an anti-oxidant N-acetylcystein significantly improved pulmonary emphysema and dysfunction. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 05/01/1997 - "The half maximum inhibition concentrations of ONO-3403 toward BxPC-3 pancreatic carcinoma, T24 bladder carcinoma and A431 epidermoid carcinoma cells were 20-30 mu g/ml whereas those toward pancreatic carcinomas, PANC-1 and Mia PaCa-2, were 60-80 mu g/ml. Since FOY-305 has been shown to be effective in chemotherapy for human oral cancer, ONO-3403 is expected to be a more effective anticancer drug."
5.	Mouth Neoplasms (Oral Cancer) 05/01/1997 - "The half maximum inhibition concentrations of ONO-3403 toward BxPC-3 pancreatic carcinoma, T24 bladder carcinoma and A431 epidermoid carcinoma cells were 20-30 mu g/ml whereas those toward pancreatic carcinomas, PANC-1 and Mia PaCa-2, were 60-80 mu g/ml. Since FOY-305 has been shown to be effective in chemotherapy for human oral cancer, ONO-3403 is expected to be a more effective anticancer drug."

Related Drugs and Biologics

1.	camostat
2.	Serine Proteinase Inhibitors (Serine Protease Inhibitors)
3.	Antioxidants
4.	Serine Proteases (Serine Protease)
5.	ErbB Receptors (EGF Receptor)
6.	Urokinase-Type Plasminogen Activator (Urokinase)
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8.	Trypsin Inhibitors
9.	Trypsin
10.	Taurocholic Acid (Sodium Taurocholate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration